Arvinas and 3SBio hope to do better
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Backed by ASCO data Arcus guns for phase 3
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Avenzo takes a second shot at CDK-selective inhibition
AVZO-023 follows AVZO-021 into clinical trials.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
AbbVie's telisotuzumab conjugate take two
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
